New appointment

Probiotix Health PLC
31 January 2024
 

ProBiotix Health plc

("ProBiotix" or the "Company")

 

New appointment

 

ProBiotix Health plc (AQUIS: PBX), a life sciences business developing probiotics to support cardiometabolic health, announces that Mads Brandt has joined the Company as Global Supply Chain Director. Mads's appointment became effective from 1 December 2023, and is part of the Company's strategy to bring experts on board to support the future growth plans for the Company.

 

Mads has over 20 years' experience in working in the supply chain space, and has a broad understanding of logistics, management consultancy and operations. He is driven by his leadership skills and vast expertise in the medical device, pharma and medtech industries. He has previously worked for a number of global organisations such as ISS A/S, PA Consulting Group and LEO Pharma where he held various key senior management positions.

 

Steen Andersen, CEO of ProBiotix Health plc commented: "On behalf of the team at ProBiotix, I would like to welcome Mads as our new Global Supply Chain Director and I know he will be a great asset to the Company. He brings an extensive skillset in the supply chain field, which can help greatly in supporting operational, tactical and strategical aspects of operations at a global scale.

 

"With his considerable experience, he can help us to build and optimise our supply chain, improve on and capitalise on our partnerships with existing and potentially new CMO's, creating an agile and stable supply chain to create a platform for growth and help us to plan our future with efficiency. He will allow us to be even more innovative in our approach to product solutions to cater for our customer and market needs."

 

For further information, please contact:

 

ProBiotix Health plc

https://probiotixhealth-ir.com/

Steen Andersen, Chief Executive

Contact via Walbrook below



Peterhouse Capital Limited (Aquis Corporate Adviser and Broker)

Tel: 020 7469 0930

Mark Anwyl


Duncan Vasey


 


Walbrook PR Ltd

probiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings